

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Cutia Therapeutics

科笛集团

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2487)

OPERATIONAL UPDATE FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2024

This announcement is made by the board of directors (the “**Board**”) of Cutia Therapeutics (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide an operational update on the business of the Group.

Sales Performance for the Nine Months Ended 30 September 2024

For the nine months ended 30 September 2024, revenue of the Group’s commercialized products amounted to approximately RMB148.9 million, representing a positive growth of approximately 129.9% as compared to the same period in 2023.

The sales performance data do not constitute, represent or indicate the full picture of the Group’s earnings or financial performance.

This announcement is based on the Board’s preliminary review of the draft unaudited operational data of the Group and the information currently available to the Board, and is not based on any data and information audited or reviewed by the independent auditor of the Group. The information contained in this announcement may be subject to change or adjustment. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board

Cutia Therapeutics

Zhang Lele

Chief Executive Officer and Executive Director

Hong Kong, 31 October 2024

As at the date of this announcement, the Board comprises (i) Ms. Zhang Lele and Mr. Huang Yuqing as executive directors; (ii) Dr. Chen Lian Yong, Dr. Xie Qin, Dr. Huang Xiao and Ms. Yang Yunxia as non-executive directors; and (iii) Mr. Chung Ming Kit, Mr. Tao Tak Yan Dennis and Mr. Ye Xiaoxiang as independent non-executive directors.